The objective of this presentation is to appreciate what medication changes and additions help which women with hypoactive sexual desire disorder. The biochemistry of female hypoactive sexual desire disorder must be viewed in context of new understanding of female sexual response and new understanding of female \"sex receptors\" or biochemistry of sexual desire. Pharmacodynamics of Dopamine, Serotonin, Prolactin, Nitric Oxide, (Testosterone and Estrogen) will be discussed.
Conflict of Interest: Advisory Board Of Procter And Gamble, Lilly-Icos National Speaker For The Following Pharmaceutical Companies: Forest, Wyeth, Cephalon
Financial Support/Funding: None disclosed
Sydney, Australia, April 2007